Dexcom was one of the first companies to announce that it would have an Apple Watch app, and a recent FDA guideline made it clear that, as a secondary display device for a cleared CGM, the Apple Watch app wouldn't require its own clearance.
But users of other smartwatches, including the Pebble Watch and the Android devices have also had access to Dexcom CGM readings, just not through an...
The Dexcom G4 receiver, which will have an "identical" form factor to the forthcoming Bluetooth version.
In a call to investors days after its app won FDA approval, Dexcom CEO Kevin Sayer shared some of the company's follow-up plans for its new smartphone-connected continuous glucose monitor, including Android and smartwatch apps and apps that will run some analytics on the CGM data.
Dexcom...
The old Dexcom Share, with charging cradle.
Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor data to be transferred directly to a user's smartphone, as well as the smartphones of up to five friends or caretakers.
Dexcom Share got clearance in...
The Dexcom G4 was the continuous glucose monitor used in the study.
An artificial pancreas system -- consisting of a continuous glucose monitor, and insulin pump, and an iPhone 4s -- has been shown to improve glucose regulation in a simulated outpatient setting in both adults and adolescents with Type 1 diabetes, according to a new paper in the New England Journal of Medicine. The adult...
San Diego-based Dexcom, a maker of continuous glucose monitors, has filed for a patent for a system that would integrate a smartphone with a Dexcom device, detailing some of the features such a device might have.
"The present embodiments harness a wide variety of capabilities of modern smartphones, and combine these capabilities with information from a continuous glucose monitor to provide...
Scientific American recently published a feature on wireless enabled and needle-free, continuous blood glucose monitoring company Echo Therapeutics, which was one of the few startups in wireless health that announced venture capital investment last year. Echo is currently seeking NDA clearance from the FDA. According to Scientific American, Echo's offering, Symphony tCGM, has three distinct...
